Control
Apr 21 2023 |
et al., Pharmaceuticals, doi:10.3390/ph16040631 | Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial |
| 69% higher mortality (p=0.37) and 45% worse improvement (p=0.56). RCT 68 hospitalized COVID-19 patients with cytokine storm showing no significant improvement in clinical outcomes with pentoxifylline (PTX) treatment compared to standard therapy. While PTX demonstrated positive effects on inflammatory bi.. | ||
Dec 31 2021 |
et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.108227 | Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial |
| 540% higher mortality (p=0.25). RCT 72 hospitalized COVID-19 patients showing no significant difference in clinical outcomes with pentoxifylline treatment compared to placebo. | ||
Jan 31 2021 |
et al., International Immunopharmacology, doi:10.1016/j.intimp.2020.107209 | Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study |
| 65% lower mortality (p=0.18), 54% lower ventilation (p=0.36), and 15% shorter hospitalization (p=0.33). Pilot study of 38 hospitalized COVID-19 patients in Mexico showing pentoxifylline treatment was associated with significantly increased lymphocyte count and decreased LDH levels compared to standard care. The pentoxifylline group (400mg t.. | ||